INTRODUCTION

With the considerable increase in the life expectancy of HIV-infected patients in the age of highly-powerful antiretroviral therapy (ART), some of the consequences of prolonged viral infection and that treatment have been seen. The metabolic consequences occurring within this context are explored in several publications in the literature, especially the lipodystrophy syndrome. Currently, the increasing observation of osteoarticular changes in these patients is the subject of more detailed study, with the aim of detecting their possible causes and determining the most appropriate therapeutic approach.

Among the complex metabolic changes in chronic HIV infection and its treatment, there is a decrease of bone mineralization in a high proportion of patients resulting from various factors present in the host itself, in the virus, and in the antiretroviral drugs (ARV). Bone is continuously remodeled by the synchronization of its formation and resorption, which can be deregulated during HIV infection. Bone mineralization decreases, causing osteopenia, which can result in osteoporosis.

The osteoarticular changes most frequently reported in patients infected for a long period with HIV and using ART are osteopenia/osteoporosis, osteonecrosis, carpal tunnel syndrome, and adhesive capsulitis of the shoulders.

Osteopenia/osteoporosis

According to the World Health Organization, the definitions of osteopenia and osteoporosis are based on bone densitometry results (1). Osteoporosis is defined as when this ratio is less than 2 times the standard deviation, and osteopenia when the result is between -1 and -2 times the standard deviation (2). Osteoporosis can be considered severe when, in addition to this criterion, the patient has a fracture (Figure 1).

Several studies have shown a high prevalence of these abnormalities in patients infected with HIV, according to these criteria (1-4,6-11). Multiple factors have been reported as causes of osteopenia, including the direct effects of the virus on osteogenic cells;
There have been studies regarding the influence of antiretroviral therapy that show an increased risk when using protease inhibitors (PI), since indinavir is known to inhibit bone formation and ritonavir is known to inhibit osteoclast differentiation and function\(^{(1,6,7,9-11)}\). Recent reports on reverse transcriptase inhibitors have linked tenofovir to the occurrence of osteomalacia and Fanconi syndrome\(^{(12)}\). Still other factors may contribute to accelerated bone loss, such as nutritional deficiency, low serum calcium levels, immobilization, hypogonadism, hyperthyroidism, hyperparathyroidism, renal failure, use of opioids or heroin, use of corticosteroids, postmenopause in women, and alcohol consumption greater than 16g/day\(^{(1,8)}\) (Figures 3 and 4).

### Figure 1 – Graphical representation of the normal ranges and changes in bone mineral density based on standard deviation from the general population.

### Figure 2 – Biochemical markers of bone metabolism.

There have been studies regarding the influence of antiretroviral therapy that show an increased risk when using protease inhibitors (PI), since indinavir is known to inhibit bone formation and ritonavir is known to inhibit osteoclast differentiation and function\(^{(1,6,7,9-11)}\). Recent reports on reverse transcriptase inhibitors have linked tenofovir to the occurrence of osteomalacia and Fanconi syndrome\(^{(12)}\). Still other factors may contribute to accelerated bone loss, such as nutritional deficiency, low serum calcium levels, immobilization, hypogonadism, hyperthyroidism, hyperparathyroidism, renal failure, use of opioids or heroin, use of corticosteroids, postmenopause in women, and alcohol consumption greater than 16g/day\(^{(1,8)}\) (Figures 3 and 4).

### Figure 3 – Meta-analysis: risk of osteoporosis in HIV patients and control population.

### Figure 4 – Algorithm: investigation and prevention of complications of decreased bone mineral density.

The main form of osteoporosis treatment is prevention, conducted by encouraging physical activity and proper nutrition in the first three decades of life in order to reach maximum bone mass formation.

Calcium intake and supplementary vitamin D should be part of any therapeutic regimen for osteoporosis. In postmenopausal women, hormone replacement therapy is an important method of prevention of osteoporosis. As for drug therapy, there are basically two classes of medications: bone antiresorptive agents and bone formation-stimulating agents.

### Osteonecrosis

The occurrence of osteonecrosis in patients with HIV has been reported since 1990, with incidences that are progressively increasing and higher than the general population\(^{(13)}\). The annual incidence of symptomatic osteonecrosis in the general population is estimated between 0.010 and 0.135%\(^{(13)}\).

Recent studies using magnetic resonance imaging
(MRI) to detect osteonecrosis in patients with HIV have estimated its incidence to be approximately 4%. The incidence of bilateral ranges from 35 to 80%.

In the general population, there are some known risk factors and conditions associated with the development of osteonecrosis, such as the use of systemic corticosteroids, alcoholism, hyperlipidemia, sickle cell anemia, coagulopathies, Gaucher’s disease, systemic lupus erythematosus, rheumatoid arthritis, hyperuricemia and gout, radiation therapy, obesity, pancreatitis, fracture sequelae, chemotherapy, vasculitis, and smoking. Besides these factors, in the development of osteonecrosis in patients infected with HIV, we also have dyslipidemia, the use of megestrol acetate and steroids, testosterone replacement, as well as the forms of vasculitis that predispose the patient to intraosseous thrombosis by the presence of anticardiolipin antibodies and by a deficiency of S protein. Moreover, the antiretroviral therapy itself may be related to the increasing development of osteonecrosis.

For the diagnosis of osteonecrosis, clinical signs should be observed, such as the presence of joint pain and limitations in the range of motion. The most frequently involved joints are the hips, unilaterally or bilaterally, the knees, ankles, elbows, and shoulders.

It should be noted that the interval between radiological changes and clinical symptoms can be long, ranging from three to eight years. Simple radiographs of the joint have low diagnostic sensitivity early in the disease. The radiological findings frequently indicating osteonecrosis include cystic sclerosis, subchondral radiolucency, bone collapse, and degenerative joint changes. Computed tomography without contrast adds little information to ordinary radiographs. MRI has 99% sensitivity and specificity for diagnosis from the earliest phase. Bone scintigraphy can be used to determine its stage and in the search for hidden asymptomatic foci, although it is not very specific.

Treatment varies with the stage of the disease. In patients with HIV, it is important to exclude or control other risk factors that are not part of the disease itself or the antiretroviral drug. In oligosymptomatic individuals, treatment may be based on the use of analgesics and non-hormonal anti-inflammatory drugs.

Decompression procedures can be used in the area of necrosis in the early stages, with or without free or pedicled cortico-spongious grafts. With disease progression, when changes in articular congruence begin, procedures such as osteotomies, unicompartmental arthroplasty or hemiarthroplasties may be indicated, and in more advanced cases, the solution is total arthroplasty.

**Carpal tunnel syndrome**

The incidence in the general population is around 3.8% with clinical examination and, when electroneuromyography is used, it is 2.7%. In the HIV-positive population, the incidence has remained very close to that of the general population.

This syndrome has been associated with the use of ART, especially protease inhibitors, and would result from known metabolic disorders and as myxedematous material is deposited in the carpal tunnel, with consequent nerve compression. Other factors such as professional activities, hypothyroidism, hyperglycemia, rheumatoid arthritis, obesity, and various metabolic disorders are associated with the development of this syndrome in patients with HIV/AIDS. Therefore, the direct correlation with the presence of HIV and antiretroviral therapy is still questionable.

Treatment is based on the stage of the compression syndrome. In the mild stage, treatment is conservative, with the use of nocturnal splints and the use of anti-inflammatory medications. In the moderate and severe stages, surgical treatment is indicated. This can be performed conventionally or endoscopically. In both procedures, the median nerve is decompressed through the opening of the flexor retinaculum.

**Adhesive capsulitis**

Adhesive capsulitis has been linked to HIV patients receiving an ART regimen with PIs. The reported cases are limited to shoulder involvement, suggesting that other sites are rare. The condition’s characteristic symptoms include progressive unilateral or bilateral pain in the shoulders, with restricted active and passive ranges of motion. Classically, the onset of symptoms is insidious, occurring about 12 to 14 months after initiation of the use of PIs. Simple radiographs may show bone rarefaction caused by disuse, however, magnetic resonance arthrography is the examination of choice for diagnosis. Symptoms tend to regress spontaneously after a period of six to
24 months with the institution of adequate treatment and interruption of ART\(^{(19,20)}\).

The treatment of adhesive capsulitis depends on its time course and the severity of adhesions. In milder cases, conservative treatment with analgesics, anti-inflammatory drugs, and physical therapy is the most suitable\(^{(19,21)}\). In the most severe cases, which are unresponsive to conservative treatment, arthroscopic treatment is the most suitable, followed by early mobilization. We have avoided the indication of manipulation alone due to the higher incidence of proximal humerus fractures and its more painful postoperative period, which makes early mobilization difficult\(^{(21)}\).

**DISCUSSION**

Given the prevalence and importance of osteoarticular changes, in March 2006 the IOT began caring for HIV/AIDS patients with orthopedic complaints who were referred from two referral centers for the treatment of patients infected with HIV.

From March 2006 to March 2008, of the 206 patients evaluated, 83 were enrolled in the clinic, with a total of 614 visits between initial consultations and returns.

The patients studied had prolonged HIV infection, with an average of 114 months since diagnosis. They also had prolonged exposure to ART, with a mean of 96 months of use. Among the most widely used drugs were lamivudine, zidovudine, and nelfinavir. There was a history of PI use in 72% of the sample (Figure 5).

At the time of evaluation, only 8% of patients had CD4 counts below 200 cells/mm\(^3\) and 74% had an undetectable viral load.

The most prevalent orthopedic change in this population was osteonecrosis, with an incidence of 12%. The hip joint was the most affected, with findings of bilaterality in all cases. One hundred percent bilaterality is easily explained for all cases by the origin being secondary, which raises this index (Figure 6 and Table 1).

The chief patient complaint initially consisted of only hip pain with limitation of motion and limping during evolution, following the classical clinical picture of the disease.

All patients diagnosed with osteonecrosis were in advanced stages of the disease.

This fact may indicate a disease with a more...
aggressive course or a longer delay in diagnosis, probably related to the abundant clinical manifestations of this population and little appreciation for secondary complaints. In addition, we observed a trend of more rapid clinical disease progression in this study, with more intense pain and a pattern of response to non-surgical treatment that is less favorable than that of the general population.

CONCLUSION

Osteoarticular complications show a significant prevalence in the population living with HIV receiving high-activity antiretroviral therapy, with a pattern of clinical presentation, natural disease course, and response to therapy that is different from those of the general population.

REFERENCES

1. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42(1):108-14.
2. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(3):1917-23.
3. Delaunay C, Loeuill-Peres S, Benhamou CL. Osteopenia and human immunodeficiency virus. Joint Bone Spine. 2002;69(2):105-8.
4. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Alibadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS. 2004;18(3):475-83.
5. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. British HIV Assoc. 2005;6:145-50.
6. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 2001;51(3):151-77.
7. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S101-5.
8. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277(22):19247-50.
9. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15(14):1823-9.
10. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89(1):24-8.
11. Tan BM, Nelson RP Jr, James-Yarish M, Emmuneal P, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J Pediatr. 2001;139(3):447-51.
12. Parsonage MJ, Wilkins EGL, Snowden N, Isaia BG, Savage MW. The development of hyperphosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005;6(5):341-6.
13. Mahoney CR, Glesby MJ, DiCarlo EF, Peterson MGE, Bostrom MP. Total hip arthroplasty in patients with human immunodeficiency virus infection. Acta Orthop. 2005;76(2):198-203.
14. Allison GT, Bostrom MP, Glesby MJ. Osteonecrosis in HIV disease: epidemiology, etiologies and clinical management. AIDS. 2003;17(1):1-9.
15. Allen SH, Moore AL, Tyer MJ, Holloway BJ, Johnson MA. Osteonecrosis of the knee in a patient receiving antiretroviral therapy. Int J STD AIDS. 2002;13(11):792-4.
16. Sclar G. Carpal tunnel syndrome in HIV-1 patients: a metabolic consequence of protease inhibitor use? AIDS. 2000;14(3):336-8.
17. Asensio G, Caso JAA, Rojas R. Carpal tunnel syndrome in HIV patients? AIDS. 2002;16(6):948-50.
18. Canale ST. editor. Campbell’s operative orthopaedics. 10th ed. Philadelphia: Mosby; 2003.
19. De Ponti A, Vigano MG, Taverna E, Sansone V. Adhesive capsulitis of the shoulder: a challenging case. Rheumatol Int. 2006;26(7):680-2.
20. Warner JJP, Allen A, Marks PH, Wong P. Arthroscopic release for chronic refractory adhesive capsulitis of the shoulder. J Bone Joint Surg Am. 1996;78(12):1808-16.